How much revenue did Abivax generate this year?
Abivax has achieved a revenue of 5.92 M EUR this year.
Abivax Revenue 2024
Abivax Revenue
5.92 M EUR
Ticker
ABVX.PA
ISIN
FR0012333284
WKN
A14UQC
In 2024, Abivax's sales reached 5.92 M EUR, a 0% difference from the 0 EUR sales recorded in the previous year.
The Abivax Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 850.08 | -0,01 |
| 2028e | 440.48 | -0,02 |
| 2027e | 158.68 | -0,07 |
| 2026e | 8.64 | -1,27 |
| 2025e | 76.3 | -0,14 |
| 2024e | 5.92 | -1,86 |
| 2023 | - | - |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | 0.01 | -19700,00 |
| 2013 | - | - |
Abivax Revenue, EBIT, Net Income FR0012333284 · A14UQC
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Abivax, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Abivax from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Abivax’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Abivax. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Abivax’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Abivax’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Abivax’s growth potential.
Abivax Revenue, EBIT and net profit per share
| Date | Abivax Revenue | Abivax EBIT | Abivax Net Income |
|---|---|---|---|
| 2029e | 850.08 M undefined | 0 undefined | 359.89 M undefined |
| 2028e | 440.48 M undefined | 68.23 M undefined | 189.76 M undefined |
| 2027e | 158.68 M undefined | -140.29 M undefined | 13.08 M undefined |
| 2026e | 8.64 M undefined | -192.17 M undefined | -186.33 M undefined |
| 2025e | 76.3 M undefined | -146.47 M undefined | -146.53 M undefined |
| 2024e | 5.92 M undefined | -145.89 M undefined | -165.25 M undefined |
| 2023 | 0 undefined | -127.38 M undefined | -147.74 M undefined |
| 2022 | 0 undefined | -56.6 M undefined | -69.8 M undefined |
| 2021 | 0 undefined | -42.56 M undefined | -41.36 M undefined |
| 2020 | 0 undefined | -38.01 M undefined | -37.55 M undefined |
| 2019 | 0 undefined | -33.3 M undefined | -30.63 M undefined |
| 2018 | 0 undefined | -19.11 M undefined | -15.82 M undefined |
| 2017 | 0 undefined | -14.15 M undefined | -11.22 M undefined |
| 2016 | 0 undefined | -18.24 M undefined | -14.31 M undefined |
| 2015 | 0 undefined | -18.26 M undefined | -15.95 M undefined |
| 2014 | 10,000 undefined | -5.05 M undefined | -5.08 M undefined |
| 2013 | 0 undefined | -10,000 undefined | -10,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 0 EUR | -10,000 EUR | -10,000 EUR |
| 2014 | 10,000 EUR | -5.05 M EUR | -5.08 M EUR |
| 2015 | 0 EUR | -18.26 M EUR | -15.95 M EUR |
| 2016 | 0 EUR | -18.24 M EUR | -14.31 M EUR |
| 2017 | 0 EUR | -14.15 M EUR | -11.22 M EUR |
| 2018 | 0 EUR | -19.11 M EUR | -15.82 M EUR |
| 2019 | 0 EUR | -33.3 M EUR | -30.63 M EUR |
| 2020 | 0 EUR | -38.01 M EUR | -37.55 M EUR |
| 2021 | 0 EUR | -42.56 M EUR | -41.36 M EUR |
| 2022 | 0 EUR | -56.6 M EUR | -69.8 M EUR |
| 2023 | 0 EUR | -127.38 M EUR | -147.74 M EUR |
| 2024e | 5.92 M EUR | -145.89 M EUR | -165.25 M EUR |
| 2025e | 76.3 M EUR | -146.47 M EUR | -146.53 M EUR |
| 2026e | 8.64 M EUR | -192.17 M EUR | -186.33 M EUR |
| 2027e | 158.68 M EUR | -140.29 M EUR | 13.08 M EUR |
| 2028e | 440.48 M EUR | 68.23 M EUR | 189.76 M EUR |
| 2029e | 850.08 M EUR | 0 EUR | 359.89 M EUR |
Abivax stock margins FR0012333284 · A14UQC
The Abivax margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Abivax. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Abivax.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Abivax's sales revenue. A higher gross margin percentage indicates that the Abivax retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Abivax's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Abivax's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Abivax's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Abivax. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Abivax's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Abivax Margin History
| Abivax Gross margin | Abivax Profit margin | Abivax EBIT margin | Abivax Profit margin |
|---|---|---|---|
| 2029e | -19,700 % | 0 % | 42.34 % |
| 2028e | -19,700 % | 15.49 % | 43.08 % |
| 2027e | -19,700 % | -88.41 % | 8.25 % |
| 2026e | -19,700 % | -2,225.2 % | -2,157.61 % |
| 2025e | -19,700 % | -191.98 % | -192.05 % |
| 2024e | -19,700 % | -2,465.95 % | -2,793.19 % |
| 2023 | -19,700 % | 0 % | 0 % |
| 2022 | -19,700 % | 0 % | 0 % |
| 2021 | -19,700 % | 0 % | 0 % |
| 2020 | -19,700 % | 0 % | 0 % |
| 2019 | -19,700 % | 0 % | 0 % |
| 2018 | -19,700 % | 0 % | 0 % |
| 2017 | -19,700 % | 0 % | 0 % |
| 2016 | -19,700 % | 0 % | 0 % |
| 2015 | -19,700 % | 0 % | 0 % |
| 2014 | -19,700 % | -50,500 % | -50,800 % |
| 2013 | -19,700 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | -19,700 % | 0 % | 0 % |
| 2014 | -19,700 % | -50,500 % | -50,800 % |
| 2015 | -19,700 % | 0 % | 0 % |
| 2016 | -19,700 % | 0 % | 0 % |
| 2017 | -19,700 % | 0 % | 0 % |
| 2018 | -19,700 % | 0 % | 0 % |
| 2019 | -19,700 % | 0 % | 0 % |
| 2020 | -19,700 % | 0 % | 0 % |
| 2021 | -19,700 % | 0 % | 0 % |
| 2022 | -19,700 % | 0 % | 0 % |
| 2023 | -19,700 % | 0 % | 0 % |
| 2024e | -19,700 % | -2,465.95 % | -2,793.19 % |
| 2025e | -19,700 % | -191.98 % | -192.05 % |
| 2026e | -19,700 % | -2,225.2 % | -2,157.61 % |
| 2027e | -19,700 % | -88.41 % | 8.25 % |
| 2028e | -19,700 % | 15.49 % | 43.08 % |
| 2029e | -19,700 % | 0 % | 42.34 % |
Abivax Aktienanalyse
What does Abivax do?
Abivax SA is a biotechnology company based in France that specializes in the development of innovative therapies for the treatment of serious health problems. The company was founded in 2013 and has been listed on the Euronext stock exchange in Paris since 2015. Abivax aims to treat a wide range of diseases, including autoimmune diseases, inflammatory processes, infectious diseases, and cancer. The company combines biological and chemical approaches to develop tailored therapies that target the specific characteristics of each disease. One of the main pillars of Abivax's business model is collaboration with leading academic and scientific institutions worldwide to translate the latest scientific knowledge into practice. Abivax is committed to proving the effectiveness and safety of its therapies through extensive clinical trials and meeting regulatory requirements. Abivax's portfolio includes several promising therapy candidates at various stages of development. One of the main products is ABX464, a novel drug against certain inflammatory diseases such as Crohn's disease and rheumatoid arthritis. The drug inhibits the activity of a specific protein in the body that plays an important role in inflammation. ABX464 has shown to be highly effective and well-tolerated in clinical trials and could potentially become a promising treatment option in the future. Another promising product is ABX196, an immunomodulator for the treatment of cancer. ABX196 has the potential to selectively activate the body's immune system and strengthen its defense against cancer cells. Preclinical studies have shown promising results, and ABX196 is currently being tested in clinical trials on patients with various types of cancer. Abivax works closely with its partners to further develop these therapy candidates and expand its pipeline. Strategic partners include leading pharmaceutical companies such as Sanofi and Boehringer Ingelheim Pharma GmbH & Co. KG. This collaboration allows Abivax to advance its research and development at the highest level and further establish its position as a leading biotechnology company. Overall, with its innovative research and promising therapy candidates, Abivax has the potential to achieve significant progress in the treatment of serious health problems. The company is expected to continue playing an important role in the biotechnology and innovative therapies market, and its products are expected to become available on the market soon. Abivax ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Abivax's Sales Figures
The sales figures of Abivax originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Abivax’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Abivax's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Abivax’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Abivax stock
How much was the turnover of the company Abivax compared to the previous year?
The revenue of Abivax has increased by 0% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Abivax?
The revenue of Abivax is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Abivax measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Abivax so important for investors?
The revenue of Abivax is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Abivax pay?
Over the past 12 months, Abivax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abivax is expected to pay a dividend of 0 EUR.
What is the dividend yield of Abivax?
The current dividend yield of Abivax is .
When does Abivax pay dividends?
Abivax pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Abivax?
Abivax paid dividends every year for the past 0 years.
What is the dividend of Abivax?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Abivax located?
Abivax is assigned to the 'Health' sector.
Wann musste ich die Aktien von Abivax kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Abivax from 11/14/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/14/2024.
When did Abivax pay the last dividend?
The last dividend was paid out on 11/14/2024.
What was the dividend of Abivax in the year 2023?
In the year 2023, Abivax distributed 0 EUR as dividends.
In which currency does Abivax pay out the dividend?
The dividends of Abivax are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Abivax stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Abivax
Our stock analysis for Abivax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abivax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
